A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
Clinical trial NCT07310420 · RECRUITING
Trial details
- NCT number
- NCT07310420
- Sponsor
- TerSera Therapeutics LLC
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-30
- Primary completion
- 2026-11-30
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.